Search
forLearn
5 / 801 resultslearn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
learn GT20029
research compound made to degrade androgen receptors in scalp
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn Biotinyl-GHK
Research
5 / 690 resultsresearch The Secretome of Irradiated Peripheral Mononuclear Cells Attenuates Hypertrophic Skin Scarring
PBMCsec can help reduce and improve thick skin scars.
research A concise review- Development of an analytical method and validation of dutasteride
New methods for measuring dutasteride are effective and reliable.
research CD133-positive dermal papilla-derived Wnt ligands regulate postnatal hair growth
Wnt proteins from certain skin cells are crucial for normal hair growth and renewal.
research Human umbilical cord blood mesenchymal stem cells engineered to overexpress growth factors accelerate outcomes in hair growth
Modified stem cells from umbilical cord blood can make hair grow faster.
research The role of 3Rs in the age of One Health: where we are and where we’re going
Innovative methods are reducing animal testing and improving biomedical research.
Community Join
5 / 1000+ resultscommunity Why is dutasteride approved for hair loss in Japan and South Korea but not for USA?
The reasoning for GSK's approval of dutasteride for hair loss in Japan and South Korea but not the US, with alternatives such as finasteride, minoxidil and RU58841 mentioned.
community Best Treatment In The Pipeline?
New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.
community About those dutasteride studies 😒
Dutasteride studies for hair loss are often sponsored by GlaxoSmithKline, raising concerns about potential bias. Despite this, some users report positive results with dutasteride and oral minoxidil, while others remain skeptical of industry-funded research.
community when is kintor going to start phase 3 for gt20029?
The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.
community GT20029. Kintor Pharma’s Product
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.